BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 26551667)

  • 1. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
    Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
    Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.
    Prasad A; Rabionet R; Espinet B; Zapata L; Puiggros A; Melero C; Puig A; Sarria-Trujillo Y; Ossowski S; Garcia-Muret MP; Estrach T; Servitje O; Lopez-Lerma I; Gallardo F; Pujol RM; Estivill X
    J Invest Dermatol; 2016 Jul; 136(7):1490-1499. PubMed ID: 27039262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
    Chevret E; Merlio JP
    J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
    Yumeen S; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
    Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
    Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
    Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.
    Kiessling MK; Klemke CD; Kaminski MM; Galani IE; Krammer PH; Gülow K
    Cancer Res; 2009 Mar; 69(6):2365-74. PubMed ID: 19258503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sézary syndrome: old enigmas, new targets.
    Nicolay JP; Felcht M; Schledzewski K; Goerdt S; Géraud C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):256-64. PubMed ID: 26972187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic landscape of cutaneous T cell lymphoma.
    Choi J; Goh G; Walradt T; Hong BS; Bunick CG; Chen K; Bjornson RD; Maman Y; Wang T; Tordoff J; Carlson K; Overton JD; Liu KJ; Lewis JM; Devine L; Barbarotta L; Foss FM; Subtil A; Vonderheid EC; Edelson RL; Schatz DG; Boggon TJ; Girardi M; Lifton RP
    Nat Genet; 2015 Sep; 47(9):1011-9. PubMed ID: 26192916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
    Damsky WE; Choi J
    Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
    Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
    Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.